UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000012247
Receipt number R000014317
Scientific Title Phase II study of nab-paclitaxel as second-line chemotherapy prior fluoropyrimidine resistance for metastatic or recurrent gastric cancer considering dose reduction on early points
Date of disclosure of the study information 2013/12/01
Last modified on 2017/04/10 11:54:45

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II study of nab-paclitaxel as second-line chemotherapy prior fluoropyrimidine resistance for metastatic or recurrent gastric cancer considering dose reduction on early points

Acronym

Phase II study of nab-paclitaxel as second-line chemotherapy for metastatic or recurrent gastric cancer considering dose reduction on early points (CCOG1303)

Scientific Title

Phase II study of nab-paclitaxel as second-line chemotherapy prior fluoropyrimidine resistance for metastatic or recurrent gastric cancer considering dose reduction on early points

Scientific Title:Acronym

Phase II study of nab-paclitaxel as second-line chemotherapy for metastatic or recurrent gastric cancer considering dose reduction on early points (CCOG1303)

Region

Japan


Condition

Condition

gastric cancer

Classification by specialty

Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and safety of nab-paclitaxel as second-line chemotherapy prior fluoropyrimidine resistance for metastatic or recurrent gastric cancer considering dose reduction on early points.
To evaluate the correaltion between the expression of SPARC and the efficacy of nab-paclitaxel.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

disease free survival

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

nab-paclitaxel

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Histologically or cytologically proven gastric adenocarcinoma
(2) Presence of resected primary tumor to evaluate the expression of SPARC
(3) Prior chemotherapy consisted of fluoropyrimidine for unresectable or recurrent gastric cancer
(4) No past history of treatment related paclitaxel
(5) Age : 20 years old and more
(6) Performance status (ECOG) 0-2
(7) Life expectancy : 12 weeks and more
(8) Adequate organ functions
(9) Ability to understand and willingness to sign a written informed consent before study entry

Key exclusion criteria

(1) Past history of severe hypersensitivity to drug
(2) Severe infectious disease that requires systemic treatment
(3) Second primary malignancy except in situ carcinoma or prior malignancy treated within 5 years
(4) Serious illness
(5) Congestive heart failure, unstable angina or myocardial infarction
(6) Much amount of pleural effusion, ascites or cardiac effusion
(7) Peripheral nerve disorder
(8) Presence of symptomatic or progressing CNS metastasis
(9) Psychological illness
(10) Pregnant or lactating woman. Women of child bearing potential not using a contraceptive method. Sexually active fertile men not using effective birth control.
(11) Any patients judged by the investigator to be unfit to participate in the study

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yasuhiro Kodera

Organization

Nagoya University, Graduate School of Medicine

Division name

Gastroenterorogical Surgery

Zip code


Address

65 Tsurumai-cho Showa-ku Nagoya city

TEL

052-744-2253

Email

ykodera@med.nagoya-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Daisuke Kobayashi

Organization

Nagoya University, Graduate School of Medicine

Division name

Gastroenterorogical Surgery

Zip code


Address

65 Tsurumai-cho Showa-ku Nagoya city

TEL

052-744-2253

Homepage URL


Email

kobadai@med.nagoya-u.ac.jp


Sponsor or person

Institute

Chubu Clinical Oncology Group

Institute

Department

Personal name



Funding Source

Organization

Chubu Clinical Oncology Group

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2013 Year 10 Month 31 Day

Date of IRB


Anticipated trial start date

2013 Year 12 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 11 Month 08 Day

Last modified on

2017 Year 04 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014317


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name